Logo image of KNSA

KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Fundamental Analysis

NASDAQ:KNSA - Nasdaq - GB00BRXB0C07 - Common Stock - Currency: USD

19.63  -0.39 (-1.95%)

After market: 19.63 0 (0%)

Fundamental Rating

4

KNSA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. KNSA has a great financial health rating, but its profitability evaluates not so good. KNSA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

KNSA had negative earnings in the past year.
In the past year KNSA had a positive cash flow from operations.
In multiple years KNSA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: KNSA reported negative operating cash flow in multiple years.
KNSA Yearly Net Income VS EBIT VS OCF VS FCFKNSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -1.63%, KNSA belongs to the top of the industry, outperforming 91.80% of the companies in the same industry.
The Return On Equity of KNSA (-2.08%) is better than 92.87% of its industry peers.
Industry RankSector Rank
ROA -1.63%
ROE -2.08%
ROIC N/A
ROA(3y)-8.42%
ROA(5y)-27.01%
ROE(3y)-11.95%
ROE(5y)-31.88%
ROIC(3y)N/A
ROIC(5y)N/A
KNSA Yearly ROA, ROE, ROICKNSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

1.3 Margins

The Gross Margin of KNSA (86.31%) is better than 89.48% of its industry peers.
The Profit Margin and Operating Margin are not available for KNSA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KNSA Yearly Profit, Operating, Gross MarginsKNSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

7

2. Health

2.1 Basic Checks

KNSA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KNSA has been increased compared to 1 year ago.
KNSA has more shares outstanding than it did 5 years ago.
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KNSA Yearly Shares OutstandingKNSA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
KNSA Yearly Total Debt VS Total AssetsKNSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

KNSA has an Altman-Z score of 7.04. This indicates that KNSA is financially healthy and has little risk of bankruptcy at the moment.
KNSA has a better Altman-Z score (7.04) than 82.89% of its industry peers.
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.04
ROIC/WACCN/A
WACC9.51%
KNSA Yearly LT Debt VS Equity VS FCFKNSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 3.24 indicates that KNSA has no problem at all paying its short term obligations.
With a Current ratio value of 3.24, KNSA is not doing good in the industry: 62.21% of the companies in the same industry are doing better.
A Quick Ratio of 2.95 indicates that KNSA has no problem at all paying its short term obligations.
The Quick ratio of KNSA (2.95) is worse than 63.99% of its industry peers.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 2.95
KNSA Yearly Current Assets VS Current LiabilitesKNSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

KNSA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.27%.
Looking at the last year, KNSA shows a very strong growth in Revenue. The Revenue has grown by 54.41%.
EPS 1Y (TTM)-27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)54.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%67.37%

3.2 Future

KNSA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.27% yearly.
KNSA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.05% yearly.
EPS Next Y-366.33%
EPS Next 2Y55.01%
EPS Next 3Y66.87%
EPS Next 5Y34.27%
Revenue Next Year65.23%
Revenue Next 2Y48.92%
Revenue Next 3Y38.82%
Revenue Next 5Y24.05%

3.3 Evolution

KNSA Yearly Revenue VS EstimatesKNSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KNSA Yearly EPS VS EstimatesKNSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 -3

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KNSA. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 45.39, which means the current valuation is very expensive for KNSA.
91.98% of the companies in the same industry are more expensive than KNSA, based on the Price/Forward Earnings ratio.
KNSA is valuated expensively when we compare the Price/Forward Earnings ratio to 22.65, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 45.39
KNSA Price Earnings VS Forward Price EarningsKNSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

92.69% of the companies in the same industry are more expensive than KNSA, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 127.73
EV/EBITDA N/A
KNSA Per share dataKNSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

KNSA's earnings are expected to grow with 66.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.01%
EPS Next 3Y66.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KNSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KINIKSA PHARMACEUTICALS INTE

NASDAQ:KNSA (2/24/2025, 6:30:36 PM)

After market: 19.63 0 (0%)

19.63

-0.39 (-1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2024-10-29/bmo
Earnings (Next)N/A N/A
Inst Owners96.6%
Inst Owner Change-1.3%
Ins Owners4.2%
Ins Owner Change-3.71%
Market Cap1.42B
Analysts85
Price Target36.72 (87.06%)
Short Float %4.85%
Short Ratio3.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-314.95%
Min EPS beat(2)-651.47%
Max EPS beat(2)21.57%
EPS beat(4)2
Avg EPS beat(4)-83.72%
Min EPS beat(4)-651.47%
Max EPS beat(4)345.1%
EPS beat(8)5
Avg EPS beat(8)1.41%
EPS beat(12)8
Avg EPS beat(12)27.91%
EPS beat(16)11
Avg EPS beat(16)23.19%
Revenue beat(2)1
Avg Revenue beat(2)4.23%
Min Revenue beat(2)-1.35%
Max Revenue beat(2)9.8%
Revenue beat(4)2
Avg Revenue beat(4)5.44%
Min Revenue beat(4)-1.35%
Max Revenue beat(4)13.53%
Revenue beat(8)6
Avg Revenue beat(8)11.78%
Revenue beat(12)8
Avg Revenue beat(12)9.83%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-133.33%
EPS NQ rev (3m)-133.33%
EPS NY rev (1m)-2.17%
EPS NY rev (3m)-2.17%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)0.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 45.39
P/S 3.69
P/FCF 127.73
P/OCF 126.09
P/B 3.24
P/tB 3.37
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)0.43
Fwd EY2.2%
FCF(TTM)0.15
FCFY0.78%
OCF(TTM)0.16
OCFY0.79%
SpS5.32
BVpS6.05
TBVpS5.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.63%
ROE -2.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.31%
FCFM 2.89%
ROA(3y)-8.42%
ROA(5y)-27.01%
ROE(3y)-11.95%
ROE(5y)-31.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 7.84%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.24
Quick Ratio 2.95
Altman-Z 7.04
F-Score4
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)291.8%
Cap/Depr(5y)208.32%
Cap/Sales(3y)17.69%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y-366.33%
EPS Next 2Y55.01%
EPS Next 3Y66.87%
EPS Next 5Y34.27%
Revenue 1Y (TTM)54.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%67.37%
Revenue Next Year65.23%
Revenue Next 2Y48.92%
Revenue Next 3Y38.82%
Revenue Next 5Y24.05%
EBIT growth 1Y-36.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.57%
EBIT Next 3Y53.47%
EBIT Next 5YN/A
FCF growth 1Y680.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y844.37%
OCF growth 3YN/A
OCF growth 5YN/A